Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- University of Southern California
- Study ID
- NCT00183846
- Phase
- PHASE1
- Status
- Completed
Conditions
- Bile Duct Cancer
- Duodenum Cancer
- Gastric Cancer
- Pancreatic Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- irinotecan — DRUG
- radiation therapy — PROCEDURE
Study Details
This study is for people with advanced cancer of the digestive tract and cancer that cannot be completely removed by surgery. Radiation therapy is commonly used in the treatment of these types of cancer in combination with a chemotherapy drug, called 5-fluorouracil (5-FU). In this study, doctors will administer the standard dose of radiation therapy in combination with an investigational chemotherapy drug, called irinotecan. Irinotecan can decrease the size of tumors and also appears to increase the effectiveness of radiation. The purpose of this study is to determine the highest dose of irinotecan that can be given safely in combination with radiation therapy, and to determine the side effects when these two treatments are given together. Irinotecan is approved by the Food and Drug Administration (FDA) for the treatment of colon cancer, but is not approved for cancers of the digestive tract. However, the FDA is allowing its use in this research study.
Key Dates
- Start date
- Dec 31, 2000
- Status verified
- May 2014
- Primary completion
- Oct 31, 2007
- Completion
- Jul 31, 2009
Study Design
- Enrollment
- 22 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
To determine the maximum tolerated dose of irinotecan when administered as a 5-day continuous infusion with concomitant radiation therapy in patients with upper gastrointestinal tumors (pancreas, stomach, duodenum, and common bile duct)
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| U.S.C./Norris Cancer Center | Los Angeles | California | 90033 | - |
Find similar trials in Los Angeles, CA
Related Studies
- The Gastric Cancer Foundation: A Gastric Cancer RegistryRecruiting · Stanford University · Stanford, California
- American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) RegistryRecruiting · University of Louisville · Birmingham, Alabama
- APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsPHASE2 · Recruiting · Apollomics Inc. · Los Angeles, California
- Combination of TATE and PD-1 Inhibitor in Liver CancerPHASE2 · Recruiting · Teclison Ltd. · Orange, California